Can Clinical Variables be used to Provide Better Follow up in Stereotactic Ablative Radiotherapy (SABR) Treated Lung Cancers?

SABR is an established option for medically inoperable peripheral non-small cell lung cancer (NSCLC). The optimal follow up strategy for patients following treatment with SABR has not yet been defined. Delivering follow up requires time and resource from both the patient and the healthcare provider. The aim of this study was to explore time to relapse following SABR and how clinical variables affect Local Control (LC), Progression Free Survival (PFS) and Overall Survival (OS).